Guava Leaf Extract Yields Silver-Doped Nickel Oxide Nanoparticles That Kill Glioma Cells

Glioma remains one of the most feared diagnoses in medicine, an aggressive brain tumor whose treatment options have barely expanded in decades despite enormous investment in neuro-oncology. Now, a research team spanning institutions in China, Saudi Arabia, and India reports a strikingly different approach: nanoparticles grown not in an industrial reactor but in a flask of guava leaf extract, which in laboratory tests proved capable of killing rat glioma cells with remarkable efficiency. The study, published in the journal 3 Biotech, describes the green synthesis of silver-doped nickel oxide nanoparticles and their potent cytotoxic and pro-apoptotic effects against C6 glioma cells, offering an early but tantalizing glimpse of a plant-powered route to brain cancer therapy.

The choice of Psidium guajava, the common guava, is far from arbitrary. Guava leaves are a storehouse of bioactive phytochemicals, including polyphenols, flavonoids, and terpenoids, compounds that have long been catalogued for their antimicrobial, antioxidant, and even anticancer properties in the ethnobotanical and pharmacological literature. In green synthesis, these molecules do double duty: they act as reducing agents that convert metal salt precursors, in this case nickel nitrate hexahydrate and silver nitrate, into metal and metal oxide nanoparticles, and then as capping agents that adsorb onto the particle surfaces, stabilizing them and preventing uncontrolled aggregation. This plant-mediated chemistry eliminates the need for toxic solvents and harsh synthetic conditions, aligning nanoparticle production with the principles of sustainable and environmentally benign manufacturing.

The synthesis itself is deceptively simple in concept. When the aqueous guava leaf extract meets the metal salt solution, phytochemicals reduce the metal ions, and as the reaction proceeds and is subjected to calcination, nickel oxide crystallizes into its characteristic cubic structure with silver atoms incorporated into the lattice. What distinguishes a promising nanomaterial from a chemical curiosity, however, is whether the resulting particles possess the right size, shape, crystallinity, and surface chemistry, and to establish this the team deployed a full battery of characterization techniques.

X-ray diffraction provided the structural backbone of the analysis, confirming the formation of crystalline cubic nickel oxide and demonstrating that silver had been successfully incorporated into the material rather than merely mixed alongside it. Field emission scanning electron microscopy then revealed the morphology: quasi-spherical nanoparticles arranged in an agglomerated, porous architecture. That porosity matters, because a high surface-to-volume ratio generally enhances the reactivity of nanoparticles in biological settings, increasing the contact area between particle surfaces and cell membranes. Ultraviolet-visible spectroscopy showed characteristic absorption bands at 268 and 398 nanometers, the optical fingerprints expected of the doped oxide system, while Fourier transform infrared spectroscopy confirmed both the presence of Ni-O vibrational modes and the phytochemical functional groups clinging to the particle surfaces, the molecular evidence that the guava-derived capping layer had indeed formed.

Dynamic light scattering added the final piece of the physicochemical picture, yielding a median hydrodynamic diameter of 56.50 nanometers. This figure, which measures the particle plus its surrounding shell of adsorbed molecules and solvent in suspension, sits squarely in the size range that cells readily internalize. Particles of this scale are small enough to be taken up by endocytic pathways yet large enough to carry a meaningful payload of metal ions, a balance that underpins much of modern nanomedicine design. Together, the characterization data established that the team had produced a well-defined, stable, and reproducibly synthesized nanomaterial rather than an ill-characterized mixture.

With the material verified, the researchers turned to the central question: what do these particles do to glioma cells? Using C6 rat glioma cells as the model, they exposed the cultures to increasing concentrations of the Ag-doped NiO nanoparticles over 72 hours and measured cell viability. The result was a clear concentration-dependent decline in survival, with an IC50 value, the concentration required to kill half the cells, of 24.67 micrograms per milliliter. For a first-line in vitro assessment of a green-synthesized material against an aggressive tumor type, that is a noteworthy figure, and it establishes a benchmark against which future formulations and purified analogues can be compared.

To probe how the nanoparticles were killing the cells, the team measured the release of lactate dehydrogenase, an enzyme that leaks out of cells only when their membranes are compromised. Exposure to the nanoparticles markedly increased LDH release, a signature of membrane damage and loss of cellular integrity. This finding indicates that the cytotoxicity is not a subtle metabolic slowdown but a direct assault on cell viability, consistent with mechanisms well documented for metal oxide and silver-containing nanoparticles, including the generation of reactive oxygen species that overwhelm cellular antioxidant defenses and damage lipids, proteins, and DNA.

The most visually compelling evidence came from acridine orange and ethidium bromide staining, a classic dual-fluorescence technique that distinguishes live cells from those undergoing apoptosis, the orderly program of cell death, or necrosis. Under the microscope, the difference between treated and untreated cultures was stark. In untreated controls, apoptotic cells accounted for just 7.39 plus or minus 0.92 percent of the population. After nanoparticle treatment, that figure rose to 36.67 plus or minus 1.38 percent, a nearly fivefold increase. Apoptosis is the preferred mode of cancer cell death from a therapeutic standpoint, because it disposes of tumor cells with minimal inflammation and collateral damage to surrounding tissue, and its clear induction here suggests the nanoparticles are engaging regulated death pathways rather than simply poisoning the cells indiscriminately.

The significance of these results must be read against the bleak backdrop of glioma treatment. Surgical resection, radiotherapy, and temozolomide-based chemotherapy remain the standard of care, yet the blood-brain barrier limits drug delivery, tumor infiltration into healthy brain tissue defeats complete surgical removal, and resistance to alkylating agents is common. Median survival for the most aggressive form, glioblastoma, has remained stubbornly short. Nanoparticle-based strategies have long been proposed as a way around these obstacles, since engineered particles can be designed to cross biological barriers, deliver cytotoxic payloads directly to tumor cells, and even serve as imaging agents. Metal oxide nanoparticles, in particular, have accumulated a growing body of evidence for anticancer activity across multiple tumor types, and doping, the deliberate incorporation of foreign atoms into a nanoparticle lattice, has repeatedly been shown to amplify that activity by altering electronic properties and increasing the release of therapeutic metal ions.

It bears emphasizing that this study was conducted in a cell culture model using a rat glioma line, and the road from a petri dish to a brain tumor patient is long and unforgiving. Questions of selectivity, whether the particles spare healthy neurons and glia, of biodistribution, of blood-brain barrier penetration in living organisms, and of long-term toxicity all remain open, and the authors themselves frame the work as warranting further investigation rather than as a therapy ready for the clinic. Regulatory scrutiny of metal-containing nanomedicines is also intensifying, and any candidate will need to clear rigorous safety benchmarks. Still, the convergence of green chemistry and neuro-oncology in a single experiment is what makes the study resonate. A humble guava leaf, a staple of traditional medicine across continents, has supplied the chemistry to forge a nanomaterial that pushes glioma cells toward self-destruction. If subsequent work can replicate these effects in animal models and, ultimately, in human tumors, the humble guava may earn an unexpected place in the fight against one of medicine’s most lethal cancers.

Subject of Research: Green synthesis of silver-doped nickel oxide nanoparticles using Psidium guajava leaf extract and their cytotoxic and pro-apoptotic effects on glioma cells

Article Title: Green synthesis of silver-doped nickel oxide nanoparticles using Psidium guajava leaf extract and their anti-cancer potential on glioma cells

Article References: Tan, J., Tian, J., Hou, H., Alarfaj, A. A., Arulselvan, P., & Fan, D. (2026). Green synthesis of silver-doped nickel oxide nanoparticles using Psidium guajava leaf extract and their anti-cancer potential on glioma cells. 3 Biotech, 16(10), Article 409. https://doi.org/10.1007/s13205-026-05053-x

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05053-x

Keywords: glioma, silver-doped nickel oxide nanoparticles, green synthesis, Psidium guajava, apoptosis, cytotoxicity, nanomedicine, C6 glioma cells, IC50, LDH release, brain tumor, phytochemicals